JP2023518434A5 - - Google Patents
Info
- Publication number
- JP2023518434A5 JP2023518434A5 JP2022556114A JP2022556114A JP2023518434A5 JP 2023518434 A5 JP2023518434 A5 JP 2023518434A5 JP 2022556114 A JP2022556114 A JP 2022556114A JP 2022556114 A JP2022556114 A JP 2022556114A JP 2023518434 A5 JP2023518434 A5 JP 2023518434A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- mutant protein
- sequence
- protein according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010197740 | 2020-03-19 | ||
| CN202010197740.4 | 2020-03-19 | ||
| CN202110266549 | 2021-03-11 | ||
| CN202110266549.5 | 2021-03-11 | ||
| PCT/CN2021/081840 WO2021185361A1 (zh) | 2020-03-19 | 2021-03-19 | 白介素2突变体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518434A JP2023518434A (ja) | 2023-05-01 |
| JP2023518434A5 true JP2023518434A5 (enExample) | 2024-04-02 |
Family
ID=77770497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556114A Pending JP2023518434A (ja) | 2020-03-19 | 2021-03-19 | インターロイキン２変異体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230145766A1 (enExample) |
| EP (1) | EP4122952A4 (enExample) |
| JP (1) | JP2023518434A (enExample) |
| KR (1) | KR20220155316A (enExample) |
| CN (1) | CN115698052A (enExample) |
| AU (1) | AU2021239225B2 (enExample) |
| CA (1) | CA3175717A1 (enExample) |
| TW (1) | TWI790573B (enExample) |
| WO (1) | WO2021185361A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| EP3854805A4 (en) | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| AU2021237518B2 (en) * | 2020-03-19 | 2024-08-15 | Fortvita Biologics (Singapore) Pte.Ltd. | Interleukin-2 mutant and use thereof |
| CN118598976A (zh) * | 2020-10-18 | 2024-09-06 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4406965A4 (en) * | 2021-09-22 | 2025-12-17 | Fortvita Biologics Singapore Pte Ltd | INTERLEUKIN-2 MUTANT AND FUSION PROTEIN OF WHICH |
| WO2023169524A1 (zh) * | 2022-03-10 | 2023-09-14 | 广东菲鹏制药股份有限公司 | 白细胞介素2突变体以及含有其的复合物 |
| US20240076343A1 (en) | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| CN119365482A (zh) * | 2022-06-17 | 2025-01-24 | 舒泰神（北京）生物制药股份有限公司 | 白介素-2(il-2)突变体及其用途 |
| WO2024008126A1 (en) * | 2022-07-06 | 2024-01-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Il2 muteins and uses thereof |
| CN118620056A (zh) * | 2023-03-09 | 2024-09-10 | 北京天广实生物技术股份有限公司 | Il-2变体及其用途 |
| CN118680877A (zh) * | 2023-03-21 | 2024-09-24 | 信达生物制药(苏州)有限公司 | 抗pd-1与突变il-2免疫缀合物制剂 |
| CN117116336B (zh) * | 2023-10-18 | 2024-01-23 | 深圳新锐基因科技有限公司 | 基于内部原子波动改善蛋白结构柔性弱点的方法和装置 |
| US20250195677A1 (en) * | 2023-12-19 | 2025-06-19 | Cephalon Llc | Uses for attenuated il-2 immunoconjugates |
| WO2026012466A1 (en) * | 2024-07-12 | 2026-01-15 | Vibrant Pharma Limited | Interleukin-2 muteins and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| NZ234674A (en) * | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| KR20250156190A (ko) * | 2018-06-22 | 2025-10-31 | 큐진 인크. | 인터루킨-2 변이체 및 이의 사용 방법 |
| EP3854805A4 (en) * | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| AU2021237518B2 (en) * | 2020-03-19 | 2024-08-15 | Fortvita Biologics (Singapore) Pte.Ltd. | Interleukin-2 mutant and use thereof |
| EP4406965A4 (en) * | 2021-09-22 | 2025-12-17 | Fortvita Biologics Singapore Pte Ltd | INTERLEUKIN-2 MUTANT AND FUSION PROTEIN OF WHICH |
-
2021
- 2021-03-19 JP JP2022556114A patent/JP2023518434A/ja active Pending
- 2021-03-19 US US17/911,893 patent/US20230145766A1/en active Pending
- 2021-03-19 AU AU2021239225A patent/AU2021239225B2/en active Active
- 2021-03-19 TW TW110110014A patent/TWI790573B/zh active
- 2021-03-19 EP EP21771688.5A patent/EP4122952A4/en active Pending
- 2021-03-19 CN CN202180021848.0A patent/CN115698052A/zh active Pending
- 2021-03-19 WO PCT/CN2021/081840 patent/WO2021185361A1/zh not_active Ceased
- 2021-03-19 CA CA3175717A patent/CA3175717A1/en active Pending
- 2021-03-19 KR KR1020227034880A patent/KR20220155316A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518434A5 (enExample) | ||
| JP2023518443A5 (enExample) | ||
| CN115698052A (zh) | 白介素2突变体及其用途 | |
| ES2327409T3 (es) | Proteinas de fusion fc mejoradas. | |
| KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| JP5077924B2 (ja) | 分泌された三量体受容体類似体及び生物学的活性融合タンパク質を製造するための方法及び組成物 | |
| JP2024023385A (ja) | 改善された二重特異性ポリペプチド分子 | |
| CN115057936B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2022553464A5 (enExample) | ||
| JP2015531751A (ja) | 選択的対である軽鎖および重鎖を含む免疫グロブリン構築物 | |
| JP2021533779A5 (enExample) | ||
| CN112105634A (zh) | 新型白介素2及其用途 | |
| CN112236448B (zh) | 用包含NC-1-Fc的蛋白寡聚体治疗血管发生、纤维化和癌症相关疾病的手段和方法 | |
| JP2020500015A5 (enExample) | ||
| JP7356726B2 (ja) | タンパク性ヘテロ二量体及びその使用 | |
| KR20020026558A (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| CN109963869A (zh) | 与经改造的Fc构建体相关的组合物和方法 | |
| AU2020273903B2 (en) | Novel modified immunoglobulin Fc-fusion protein and use thereof | |
| JP2024539139A5 (enExample) | ||
| JP2024507693A (ja) | 二重特異性抗体 | |
| JP2024507693A5 (enExample) | ||
| JP2026035775A (ja) | 切断可能なｃ末端電荷対タグを有する二重特異性抗体 | |
| AU2022263441A9 (en) | Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof | |
| KR20130074348A (ko) | 복수개의 단일 항체를 포함하는 단백질 복합체 | |
| JPH05304991A (ja) | Ｉｌ−２受容体重鎖に結合するポリペプチド |